Vikram Punia, President of the Pharmasyntez Group is the richest newcomer to Forbes' billionaire list. This accomplishment marks the culmination of years of hard work and innovative pharmaceutical manufacturing achievements.

With a focus on cutting-edge drug development, Pharmasyntez Group has emerged as one of Russia's leading pharmaceutical companies under Vikram Punia's direction. The business has introduced a range of innovative treatments that target different diseases to the market thanks to consistent R&D expenditures.

Vikram Punia outlined the Group's expansion plans for the production development:

“We're actively developing several strategic projects with significance for both Russian and global markets. In 2025, we'll launch our first Moscow facility—Pharmasyntez Biocapital —focusing on highly specialized production of seven antineoplastic drugs in both solid and liquid dosage forms. Responding to foreign manufacturers' departure, we're establishing another manufacturing site in Kaluga to meet dialysis consumables demand. We've already invested over 2 billion rubles in the first phase launching this year, supplemented by a 1 billion ruble loan from the Industrial Development Fund. By 2030, total infrastructure investments will reach approximately 20 billion rubles.

We're convinced Russia's pharmaceutical future lies in innovation. Our ambition extends beyond domestic needs—we're positioning ourselves in global markets. We have every opportunity for this: the country now boasts robust infrastructure with R&D and manufacturing meeting international standards.”

Being listed in Forbes attests to Vikram Punia's exceptional professionalism and strategic vision, which have enabled him to transform Pharmasyntez into a world-class enterprise. His contribution to growth of the Russian pharmaceutical sector is particularly noteworthy and deserving of respect. This accomplishment highlights Russian business people's capacity to produce excellent outcomes on a worldwide scale.v